Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IRP1 deficiency alters mitochondrial metabolism and protects against metabolic syndrome pathologies
Wen Gu, Nicole Wilkinson, Carine Fillebeen, Darren M. Blackburn, Korin Sahinyan, Eric Bonneil, Tao Zhao, Zhi Luo, Vahab D. Soleimani, Vincent Richard, Christoph H. Borchers, Albert Koulman, Benjamin Jenkins, Bernhard Michalke, Hans Zischka, Judith Sailer, Vivek Venkataramani, Othon Iliopoulos, Gary Sweeney, Kostas Pantopoulos
Wen Gu, Nicole Wilkinson, Carine Fillebeen, Darren M. Blackburn, Korin Sahinyan, Eric Bonneil, Tao Zhao, Zhi Luo, Vahab D. Soleimani, Vincent Richard, Christoph H. Borchers, Albert Koulman, Benjamin Jenkins, Bernhard Michalke, Hans Zischka, Judith Sailer, Vivek Venkataramani, Othon Iliopoulos, Gary Sweeney, Kostas Pantopoulos
View: Text | PDF
Research Article Hepatology Metabolism

IRP1 deficiency alters mitochondrial metabolism and protects against metabolic syndrome pathologies

  • Text
  • PDF
Abstract

Iron regulatory protein 1 (IRP1) is a posttranscriptional regulator of cellular iron metabolism. In mice, loss of IRP1 causes polycythemia through translational de-repression of HIF2α mRNA, which increases renal erythropoietin production. Here, we show that Irp1–/– mice develop fasting hypoglycemia and are protected against high-fat diet–induced hyperglycemia and hepatic steatosis. Discovery-based proteomics of Irp1–/– livers revealed a mitochondrial dysfunction signature. Seahorse flux analysis in primary hepatocytes and differentiated skeletal muscle myotubes confirmed impaired respiratory capacity, with a shift from oxidative phosphorylation to glycolytic ATP production. This metabolic rewiring was associated with enhanced insulin sensitivity and increased glucose uptake in skeletal muscle. Under metabolic stress, IRP1 deficiency altered the redox balance of mitochondrial iron, resulting in inefficient energy production and accumulation of amino acids and metabolites in skeletal muscles, rendering them unavailable for hepatic gluconeogenesis. These findings identify IRP1 as a critical regulator of systemic energy homeostasis.

Authors

Wen Gu, Nicole Wilkinson, Carine Fillebeen, Darren M. Blackburn, Korin Sahinyan, Eric Bonneil, Tao Zhao, Zhi Luo, Vahab D. Soleimani, Vincent Richard, Christoph H. Borchers, Albert Koulman, Benjamin Jenkins, Bernhard Michalke, Hans Zischka, Judith Sailer, Vivek Venkataramani, Othon Iliopoulos, Gary Sweeney, Kostas Pantopoulos

×

Figure 4

IRP1 deficiency causes mitochondrial dysfunction and a switch from oxidative energy metabolism to aerobic glycolysis.

Options: View larger image (or click on image) Download as PowerPoint
IRP1 deficiency causes mitochondrial dysfunction and a switch from oxida...
Mouse embryonic fibroblasts (MEFs), primary hepatocytes, and differentiated myotubes from Irp1–/– and WT mice were analyzed for mitochondrial function with the Seahorse assay. The time for addition of oligomycin, Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone, and rotenone/antimycin A or 2-deoxy-glucose (2-DG) is indicated by arrows. (A) Oxygen consumption rate (OCR) in Irp1–/– and WT MEFs. (B) Extracellular acidification rate (ECAR) in Irp1–/– and WT MEFs. (C) Lactate production by Irp1–/– and WT MEFs. (D) OCR in Irp1–/– and WT differentiated myotubes. (E) ECAR in Irp1–/– and WT differentiated myotubes. (F) OCR with palmitate as substrate in Irp1–/– and WT differentiated myotubes. (G) Glucose uptake assay in muscle fibers from Irp1–/– and WT mice. (H) OCR in Irp1–/– and WT primary hepatocytes. (I) Proton efflux rate indicating basal glycolysis in Irp1–/– and WT primary hepatocytes. Data in G and I are presented as mean ± SEM. Statistical analysis performed with 2-way ANOVA with Tukey’s multiple-comparison test; comparisons between 2 groups were done with 2-tailed Student’s t test. *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts